{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T02:33:34Z","timestamp":1696473214783},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822befc1","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T19:58:34Z","timestamp":1317758314000},"page":"603-612","source":"Crossref","is-referenced-by-count":13,"title":["Antagonist-Elicited Cannabis Withdrawal in Humans"],"prefix":"10.1097","volume":"31","author":[{"given":"David A.","family":"Gorelick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugene","family":"Schwilke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Schwope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William D.","family":"Darwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deanna L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Ortemann-Renon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Bonnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn A.","family":"Huestis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"769","DOI":"10.2174\/138955707781387920","article-title":"The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.","volume":"7","author":"Basavarajappa","year":"2007","journal-title":"Mini Rev Med Chem"},{"key":"R2-11-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.beem.2008.10.013","article-title":"An introduction to the endocannabinoid system: from the early to the latest concepts.","volume":"23","author":"De Petrocellis","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"suppl 1","key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1016\/j.psyneuen.2009.04.007","article-title":"Sex differences in the cannabinoid regulation of energy homeostasis.","volume":"34","author":"Farhang","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14728210902736568","article-title":"Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.","volume":"14","author":"Janero","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/09540260902782828","article-title":"The endocannabinoid system in neuropathological states.","volume":"21","author":"Orgado","year":"2009","journal-title":"Int Rev Psychiatry"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1161\/HYPERTENSIONAHA.105.063651","article-title":"Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations.","volume":"52","author":"Pacher","year":"2008","journal-title":"Hypertension"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/bjp.2008.130","article-title":"The endocannabinoid system in brain reward processes.","volume":"154","author":"Solinas","year":"2008","journal-title":"Br J Pharmacol"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/09540260902782786","article-title":"Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders.","volume":"21","author":"Beardsley","year":"2009","journal-title":"Int Rev Psychiatry"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/156802608783498050","article-title":"CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications.","volume":"8","author":"Jagerovic","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"482","DOI":"10.2174\/156802609788897844","article-title":"The current status and future perspectives of studies of cannabinoid receptor 1 antagonists as anti-obesity agents.","volume":"9","author":"Lee","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-09-0511","article-title":"Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.","volume":"161","author":"Butler","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","article-title":"Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies.","volume":"13","author":"Le Foll","year":"2008","journal-title":"Addict Biol"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00213-010-1790-2","article-title":"Randomized, controlled, double-blind trial of taranabant for smoking cessation.","volume":"209","author":"Morrison","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2008.09.001","article-title":"Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.","volume":"23","author":"Scheen","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/JCP.0b013e318172b8bc","article-title":"Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: results from a placebo-controlled, double-blind trial.","volume":"28","author":"Soyka","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/3-540-26573-2_24","article-title":"Cannabinoid tolerance and dependence.","volume":"168","author":"Lichtman","year":"2005","journal-title":"Handb Exp Pharmacol"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1124\/jpet.110.168435","article-title":"Rimonabant-induced 9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.","volume":"334","author":"Stewart","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","article-title":"The future of endocannabinoid-oriented clinical research after CB1 antagonists.","volume":"205","author":"Le Foll","year":"2009","journal-title":"Psychopharmacology (Berl)"},{"key":"R20-11-20210128","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1176\/appi.ajp.161.11.1967","article-title":"Review of the validity and significance of cannabis withdrawal syndrome.","volume":"161","author":"Budney","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s002130000657","article-title":"Bupropion SR worsens mood during marijuana withdrawal in humans.","volume":"155","author":"Haney","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/clpt.1992.100","article-title":"Characterization of the absorption phase of marijuana smoking.","volume":"52","author":"Huestis","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1001\/archpsyc.58.4.322","article-title":"Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716.","volume":"58","author":"Huestis","year":"2001","journal-title":"Arch Gen Psychiatry"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1749-6632.1976.tb49901.x","article-title":"Clinical studies of cannabis tolerance and dependence.","volume":"282","author":"Jones","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1207\/s15327752jpa4906_2","article-title":"Factor structure of the SCL-90-R: is there one?","volume":"49","author":"Cyr","year":"1985","journal-title":"J Pers Assess"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/sleep\/4.1.93","article-title":"The St. Mary's Hospital Sleep Questionnaire: a study of reliability.","volume":"4","author":"Ellis","year":"1981","journal-title":"Sleep"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.drugalcdep.2008.12.010","article-title":"Reliability and validity of a short form of the Marijuana Craving Questionnaire.","volume":"102","author":"Heishman","year":"2009","journal-title":"Drug Alcohol Depend"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.chroma.2007.06.069","article-title":"Simultaneous quantification of 9-tetrahydrocannabinol, 11-hydroxy-9-tetrahydrocannabinol, and 11-nor-9-tetrahydrocannabinol-9-carboxylic acid in human plasma using two-dimensional gas chromatography, cryofocusing, and electron impact-mass spectrometry.","volume":"1163","author":"Lowe","year":"2007","journal-title":"J Chromatogr A"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s002130050848","article-title":"Abstinence symptoms following oral THC administration to humans.","volume":"141","author":"Haney","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1373\/clinchem.2008.122119","article-title":"9-tetrahydrocannabinol (THC), 11-hydroxy-THC, and 11-nor-9-carboxy-THC plasma pharmacokinetics during and after continuous high-dose oral THC.","volume":"55","author":"Schwilke","year":"2009","journal-title":"Clin Chem"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.clpt.2005.12.177","article-title":"Rimonabant pharmacokinetics in healthy and obese subjects.","volume":"79","author":"Turpault","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-007-0861-5","article-title":"Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users.","volume":"194","author":"Huestis","year":"2007","journal-title":"Psychopharmacology (Berl)"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00213-005-0234-x","article-title":"The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats.","volume":"184","author":"Need","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/0024-3205(95)00174-5","article-title":"Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist.","volume":"56","author":"Rinaldi-Carmona","year":"1995","journal-title":"Life Sci"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0014-5793(94)00773-X","article-title":"SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.","volume":"350","author":"Rinaldi-Carmona","year":"1994","journal-title":"FEBS Lett"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201110000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,10]],"date-time":"2021-04-10T06:16:57Z","timestamp":1618035417000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201110000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822befc1","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}